SEC Form 4 · accession 0000899243-19-000160
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Prestrelski
Officer — Chief Scientific Officer
Period of report
Dec 24, 2018
Accepted (ET)
Jan 2, 2019 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 24, 2018 | M | 15,720 | $1.19 | A | 505,044 | D | |
| Common StockF1 | Dec 26, 2018 | S | 15,720 | $15.823 | D | 489,324 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.19 | Dec 24, 2018 | M | 15,720 | D | — | Dec 26, 2023 | Common Stock | 15,720 | 0 | D |
Explanation of responses
- F1$15.823 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.50 to $16.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2This option is currently exercisable.